Insight

Erman Akkus: Should up-front SRS be added to TKI in brain metastatic EGFR/ALK positive NSCLC?

Photo from Erman Akkus/X

Jul 25, 2024, 14:02

Erman Akkus: Should up-front SRS be added to TKI in brain metastatic EGFR/ALK positive NSCLC?

Erman Akkus, Medical Oncologist at Ankara University, shared a paper by Luke R.G. Pike et al. on X:

“Should up-front SRS be added to TKI in brain metastatic EGFR/ALK+ NSCLC?

Improves time-to-CNS progression HR: 0.63 (0.42 to 0.96), P = .033
No difference in OS
More than 20% of patients had >11 brain metastases.”

Source: Erman Akkus/X

Erman Akkus

Authors: Luke R.G. Pike, Emily Miao, Lillian A. Boe, Tejas Patil, Brandon S. Imber, Nathaniel J. Myall, Erqi L. Pollom, Caressa Hui, Vera Qu, Jacob Langston, Veronica Chiang, Michael Grant, Sarah B. Goldberg, Joshua D. Palmer, Rahul N. Prasad, Tony J.C. Wang, Albert Lee, Catherine A. Shu, Lanyi Nora Chen, Nicholas J. Thomas, Steve E. Braunstein, Brian D. Kavanagh, D. Ross Camidge, Chad G. Rusthoven

Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC)

Albert Lee ALK Brandon S. Imber Brian D. Kavanagh cancer Caressa Hui Catherine A. Shu Chad G. Rusthoven D. Ross Camidge EGFR Emily Miao Erman Akkus Erqi L. Pollom Jacob Langston Joshua D. Palmer Journal of Clinical Oncology Lanyi Nora Chen Lillian A. Boe Luke R. G. Pike Michael Grant Nathaniel J. Myall Nicholas J. Thomas NSCLC OncoDaily Oncology Rahul N. Prasad Sarah B. Goldberg Steve E. Braunstein Tejas Patil Tony J.C. Wang Vera Qu Veronica Chiang

FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment

Oncologist Near Me - Hagop Kantarjian: A Legend in Leukemia Research and Treatment

New Paper Alert: Botensilimab and Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Best of ASCOGI25

Egypt Cancer Society (ECS) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care